Show simple item record

dc.contributor.authorCoviello, Andrea D.en_US
dc.contributor.authorBremner, William J.en_US
dc.contributor.authorAmory, John K.en_US
dc.contributor.authorMatsumoto, Alvin M.en_US
dc.contributor.authorAnawalt, Bradley D.en_US
dc.contributor.authorPage, Stephanie T.en_US
dc.contributor.authorHerbst, Karen L.en_US
dc.date.accessioned2008-10-17T20:43:05Z
dc.date.available2008-10-17T20:43:05Z
dc.date.issued2005-01en_US
dc.identifier.citationJ Androl. 2005 Jan-Feb;26(1):85-92en_US
dc.identifier.urihttp://hdl.handle.net/1773/4457
dc.description.abstractTestosterone (T) administration to men increases lean body mass and decreases fat mass. Adiponectin is produced by adipocytes and is thought to influence insulin sensitivity. In this study, we sought to determine whether experimental alterations in serum T change adiponectin levels in normal men. We measured adiponectin levels in 28 healthy men ages 18-35 years before and during treatment with a potent gonadotropin-releasing-hormone (GnRH) antagonist, acyline. Decreased T levels led to increased serum adiponectin within 7 days; maximal adiponectin levels were reached on day 21 (baseline 8.6 +/- 0.9 compared with 12.2 +/- 1.0 microg/mL on day 21, P <.05) and persisted through day 30, despite no significant changes in body mass index (BMI) and an increase in leptin. The addition of T to acyline, maintaining serum T levels within the normal range, prevented the increase in adiponectin following acyline alone. In a second study, 25 men aged 55-85 years were treated with 3 weeks of high-dose T (testosterone enanthate [TE], 600 mg/wk intramuscularly). With high serum T levels, adiponectin levels decreased significantly by day 21 of treatment (baseline 14.3 +/- 1.9 compared with 10.8 +/- 1.5 microg/mL, P <.05 vs baseline and placebo), BMI slightly increased, and leptin levels were decreased. We conclude that adiponectin levels increase within days of experimental T deficiency in normal men, and the increase in adiponectin is prevented by T replacement. Furthermore, supraphysiologic T administration results in decreased adiponectin levels. Our data support the hypothesis that T, its metabolites, or both directly suppress adipocyte production of adiponectin.en_US
dc.language.isoen_USen_US
dc.publisherAmerican Society of Andrologyen_US
dc.subjecthypogonadalen_US
dc.subjectandrogenen_US
dc.subjectleptinen_US
dc.subject.meshGonadorelin, antagonists & inhibitorsen_US
dc.subject.meshComparative Studyen_US
dc.subject.meshIntercellular Signaling Peptides and Proteins, blooden_US
dc.subject.meshMaleen_US
dc.subject.meshHumansen_US
dc.subject.meshAdulten_US
dc.subject.meshTestosterone, blood, deficiency, pharmacologyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOligopeptides, pharmacologyen_US
dc.subject.meshLeptin, blooden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshBody Mass Indexen_US
dc.subject.meshAgeden_US
dc.subject.meshResearch Support, U.S. Gov't, P.H.S.en_US
dc.subject.meshAdiponectinen_US
dc.subject.meshAdolescenten_US
dc.titleTestosterone administration suppresses adiponectin levels in menen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record